DolPHIN-2 Final Results: More Rapid Virologic Suppression With DTG- vs EFV-Based ART Started in Late Pregnancy Through 72 Wks Postpartum

March 6-10, 2021; Virtual
Superior virologic efficacy observed with DTG-based regimen vs EFV-based regimen throughout pregnancy and through the breastfeeding period: final results of the DolPHIN-2 study.
Format: Microsoft PowerPoint (.ppt)
File Size: 181 KB
Released: March 10, 2021


Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Slides from CCO: ART in Pregnancy: guideline recommendations and supporting data, pharmacokinetic considerations, and drug-drug interactions

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Jonah Musa, MBBS, MSCI, PhD Released: October 20, 2021

Perspective on continuation of BIC/FTC/TAF in suppressed patients who become pregnant, from Clinical Care Options (CCO) and Dr. William R. Short

William R. Short, MD, MPH, AAHIVS Released: October 15, 2021

Concise Clinical Care Options (CCO) presentation by Nicholas Chamberlain, MD, on investigational HIV PrEP strategies in various stages of development

Nicholas Chamberlain, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: October 15, 2021 Expired: October 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.